Sign in

You're signed outSign in or to get full access.

Siamack Alavi

Director at La Rosa Holdings
Board

About Siamack Alavi

Independent director at La Rosa Holdings Corp. (LRHC) since October 2024; age 62. Background spans 40 years as an executive and entrepreneur across health and wellness, digital marketing, franchising, and sports nutrition. Founder/operator of several private businesses; Board cites his corporate governance, strategic business development, and large-scale operations experience as qualifications to serve, including as an independent committee member and committee chair. Independence affirmed under Nasdaq rules and SEC Rule 10A‑3(b)(1).

Past Roles

OrganizationRoleTenureCommittees/Impact
Salt Scene Halotherapy CenterOwner/Operator2018–2020Expanded services through partnerships; focused on profitability and customer loyalty
YMD Facial Plastic SurgeryBusiness ManagerSince 2020Streamlined operations and cost-saving measures; increased client engagement via marketing

External Roles

OrganizationRoleTenureFocus/Scope
Muscle MediaFounder/OwnerSince 2012Global fitness and health media outlet
Infinite Labs DigitalOwner/OperatorSince 2016Digital marketing agency (B2B/B2C growth)
The IV LoungeOwner/OperatorSince 2020IV hydration and wellness programming clinic
Direct Preventive CareFounder/OwnerSince 2023Preventive healthcare clinic

Board Governance

  • Independence: Board determined Alavi is independent under Nasdaq rules and SEC Rule 10A‑3(b)(1).
  • Committee assignments: Chair, Compensation Committee; Member, Audit Committee; Member, Nominating & Corporate Governance Committee.
  • Committee leadership context: Audit Committee chaired by Lourdes Felix (audit financial expert); Nominating & Corporate Governance chaired by Ned L. Siegel.
  • Meetings and engagement: In FY2024, the Board met 5 times; the Audit Committee met 4 times. Director-specific attendance rates were not disclosed.
  • Board leadership structure: CEO also serves as Board Chair. Board defers separation decision to situational needs.

Fixed Compensation

ComponentPolicy/AmountPeriod/Notes
Non-employee director cash retainer$12,000 per quarterPolicy-level disclosure; cash only
Audit Committee Chair fee$3,750 per quarterPolicy-level disclosure
Compensation or Nominating Chair fee$3,000 per quarterPolicy-level disclosure
Director equity grantsAt Compensation Committee discretion; not automaticCommittee may grant equity to directors in future
Alavi – 2024 fees earned (cash)$15,000Joined Oct 4, 2024

Note: For 2024, no stock or option awards were reported for Alavi; total director pay to him was cash-only.

Performance Compensation

Metric/InstrumentDisclosure for Alavi (FY2024)Details/Terms
Stock awards (RSUs/PSUs)None disclosed2024 director compensation table shows $0 stock awards
Option awardsNone disclosed2024 director compensation table shows $0 option awards
Performance metrics tied to director payNot disclosedNo performance-based director metrics detailed
Clawback provisions (director equity)Plan/policy framework existsCommittee controls equity timing/terms; legal/insider information safeguards described

Other Directorships & Interlocks

CategoryDisclosure
Current public company directorshipsNone disclosed for Alavi in the proxy biography
Committee interlocksCompany reports no compensation committee interlocks (no cross-service by executives)
Private/non-profit/academic boardsNot disclosed in proxy for Alavi beyond operating roles listed above

Expertise & Qualifications

  • Expertise: Corporate governance, strategic business development, entrepreneurial leadership across multiple sectors (health/wellness, digital marketing, franchising, sports nutrition).
  • Board qualification rationale: Board cites experience managing large-scale operations and delivering revenue growth; deemed well-qualified to serve as independent member and committee chair.
  • Education: Not disclosed in Alavi’s biography within the proxy.

Equity Ownership

HolderShares Beneficially Owned% of CommonNotes
Siamack Alavi (Director)600<1%Based on 1,225,046 shares outstanding on record date
Pledging/HedgingProhibited by insider trading policy (Oct 2025)Policy bans pledging, puts/calls, short selling; supports alignment
Ownership guidelinesNot disclosedNo director ownership guideline disclosure in proxy sections reviewed

Insider Trades and Section 16 Compliance

YearAlavi listed for filing delinquency?Source
FY2025No delinquency noted for Alavi; delinquencies cited for other insiders (Santos; Joseph & Deana La Rosa)Section 16(a) compliance disclosure

Related-Party Exposure (Conflicts Context)

  • Company-level related-party transactions primarily involve the CEO and his family (office leases with entities controlled by CEO and sibling director; consulting arrangement with sibling director terminated by end of 2024; family employment and acquisition from CEO affiliate). No transactions involving Alavi are disclosed.
  • Audit Committee (of which Alavi is a member) reviews/approves all related-party transactions under written charter and related person transaction policy, mitigating conflict risk through oversight.

Compensation Committee Analysis

  • Composition: Three independent directors; chaired by Alavi.
  • Responsibilities: Oversees compensation strategy; approves executive and non-employee director pay; reviews employment and severance/change-in-control arrangements; administers equity plans; reviews compensation risk.
  • Consultant use: Proxy does not disclose use of external, independent compensation consultants; the committee “may” utilize peer metrics.

Governance Assessment

  • Positive signals:
    • Independent director; chairs Compensation Committee and serves on Audit and Nominating, strengthening independent oversight in a company with CEO/Chair duality.
    • Cash-only director pay for 2024 and modest beneficial ownership (600 shares); insider trading policy prohibits pledging/hedging, supporting alignment and risk control.
    • No Section 16 filing delinquencies reported for Alavi.
  • Areas to monitor / RED FLAGS:
    • CEO/Chair duality persists; while allowed, it increases reliance on strong independent committees (where Alavi has a leading role).
    • Extensive related-party transactions with CEO and family (leases, affiliate acquisition, family employment); although none involve Alavi, they heighten the importance of rigorous Audit/Compensation/Nominating oversight.
    • Director-level attendance rates are not disclosed; Board (5 meetings) and Audit (4) met in 2024, but no per-director attendance detail to gauge individual engagement.

Overall: Alavi’s independence and committee leadership (Compensation Chair; Audit/Nominating member) bolster governance checks in an issuer with concentrated control dynamics and disclosed related-party dealings at the CEO/family level. Continued scrutiny of related-party approvals, executive pay structures, and potential adoption of director equity (if any) will be key to investor confidence.